-+ 0.00%
-+ 0.00%
-+ 0.00%

The RYBREVANT FASPRO™ combination program showed an overall remission rate of 77% in first-line treatment for patients with advanced head and neck cancer.

Zhitongcaijing·10/25/2026 13:49:05
Listen to the news
The RYBREVANT FASPRO™ combination program showed an overall remission rate of 77% in first-line treatment for patients with advanced head and neck cancer.